ClinicalTrials.gg
CompletedNCT04679623Updated Mar 17, 2022

Study of Midazolam in Healthy Adults

A Phase 1 interventional study of Midazolam and Seizalam in Status Epilepticus, sponsored by Rafa Laboratories. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-17.

Sponsored by Rafa Laboratories · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2021, 5 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies in Status Epilepticus with a site in United States — 13 open to participants now, 13 under way, 2 of them phase 3. Status Epilepticus · United States.

Enrollment
15th of 30
40 · median 35
Started
2021
with 6 others
Phase 1
3 of 41
none open now
Registered
26th of 41
by date

Among the 41 studies in Status Epilepticus with a site in United States, this one is the 15th largest by enrollment of the 30 interventional ones that give a count, is one of 7 that started in 2021, is one of 3 in phase 1, and was the 26th registered.

Status Epilepticus

124 studies on the registry are indexed under Status Epilepticus; 37 are open to participants now.

Browse Status Epilepticus studies →

Open to participants now

13 of the 41 studies in Status Epilepticus with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 29 Status Epilepticus studies recruiting now, 16 (55%) set no upper age limit and 8 (28%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Status Epilepticus with a site in United States, or all of them as a file.
02

Study summary

This study is a phase 1, open-label, crossover, comparison study to evaluate the safety and pharmacokinetics (PK) of a single IM administration of 10 mg midazolam using Rafa's auto-injector compared with seizalam in healthy adults. All subjects will participate in both study periods which will span 28 days following a pre study screening visit.

03

Conditions studied

  • Status Epilepticus

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Can understand and provide signed
  2. Is a healthy male or healthy, non-pregnant, non-lactating female whose screening, physical exam, labs, vitals, and are within normal range
  3. Has a willingness to comply and be available for all protocol procedures
  4. Is between age 18 and 55 years, inclusive on the day of injection
  5. If the subject is female and of , she has a negative serum pregnancy test at screening and negative urine test within 24 hours prior to injection Note: A woman is considered of childbearing potential unless (≥ 1 year without menses) or surgically sterilized via bilateral oophorectomy, or hysterectomy or bilateral tubal ligation or successful Essure placement with documented confirmation test at least 3 months after the procedure
  6. If the subject is female and of childbearing potential, she agrees to practice abstinence from sexual intercourse with men or use acceptable up to 1 month after the end of study visit Note: Acceptable contraception methods are restricted to effective devices (approved oral contraceptives, Intrauterine Contraceptive Devices, NuvaRing®)
  7. If the subject is male, he agrees to practice abstinence from sexual intercourse with women or use acceptable contraception up to 1 month after the end of study visit
  8. Has a (BMI) ≥18.0 and ≤26.0 kg/m2 at screening
  9. Has a negative urine drug screen
  10. Has a negative breathalyzer test
  11. Subject is not taking any medications or St. John's wort and agrees to avoid grapefruit juice and alcohol until study completion on Day 28
  12. Subject agrees to not take any vitamins or supplements 48 hours prior to dosing
  13. Is available for follow-up for the duration of the study

Exclusion criteria

Exclusion Criteria:

  1. Received treatment with another drug within 28 days of initial dosing
  2. Has a current or history of drug and /or alcohol abuse
  3. Is pregnant or breastfeeding woman
  4. Has or allergy to midazolam
  5. Has hypersensitivity or allergy to benzodiazepines
  6. Has a history of cardiovascular, pulmonary, neurological, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or psychiatric disease or any other reason, in the opinion of the investigator, that the patient should not participate
  7. Tests positive for -1, HIV-2, HbsAg, antibody, or syphilis
  8. Has had a blood donation in the 8 weeks prior to the study period start date
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Midazolam Injection

    Midazolam injection, 10 mg

    Combination Product: Midazolam

  • Active comparator
    Seizalam™

    Seizalam, 10 mg

    Drug: Seizalam

Interventions

06

What researchers measure

Primary outcomes

  1. number of participants with local injection site changes

    Time frame: 28 days

  2. number of participants with systemic changes in physical exam

    Time frame: 28 days

  3. number of participants with vital signs changes resulting in a serious adverse event

    Time frame: 28 days

  4. number of participants with ECG changes resulting in a serious adverse event

    Time frame: 28 days

  5. number of participants with laboratory changes resulting in a serious adverse event

    Time frame: 28 days

  6. time to reach Cmax (Tmax) will be obtained directly from the plasma concentration-time profile data for each patient following IM injection

    Time frame: 28 days

  7. The elimination rate constant (ke) will be estimated

    Time frame: 28 days

  8. The AUC from time 0 to the time of the last measurable concentration (AUC0-last) and the AUC from time zero to infinite time (AUC0-∞)

    Time frame: 28 days

Secondary outcomes

  1. Relative bioavailability will be obtained by analysis of Cmax

    Time frame: 28 days

  2. Relative bioavailability will be obtained by analysis of AUC0-last

    Time frame: 28 days

  3. Relative bioavailability will be obtained by analysis of AUC0-∞

    Time frame: 28 days

07

Study locations

1 site
  • Wake Research
    Raleigh, North Carolina 27612, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Sep 2021, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2020
First posted
Dec 22, 2020
StartActual
Jun 9, 2021
Primary completionActual
Sep 17, 2021
CompletionActual
Sep 17, 2021
Last update
Mar 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04679623
Lead sponsor
Rafa Laboratories
Collaborators
Resilience Government Services, Inc., Joint Project Management Office for Chemical, Biological, Radiological, and Nuclear Medical
Responsible party
Sponsor
First posted
Dec 22, 2020
Start date
Jun 9, 2021
Primary completion
Sep 17, 2021
Completion
Sep 17, 2021
Last update
Mar 17, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Midazolam

Start the discussion